Cancer immunotherapy drugs called PD-1 inhibitors are widely used to stimulate the immune system to fight cancer, but many patients either don't respond or develop resistance to them. A new small-molecule drug candidate being tested in an early-stage clinical trial aims to improve patient responses to immunotherapy. Now scientists have shown, in a study published today in Nature , that the small molecule works through two different mechanisms to slow tumor growth and increase survival in lab animals.

https://www.miragenews.com/immunotherapy-candidate-triggers-dual-response-1097295/

#miragenews